ACETAdicet Bio Inc

Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-market session. The market value of their outstanding shares is at $77.1 million. Bio-Techne (NASDAQ:TECH) stock movedread more...

Here is how Adicet Bio, Inc. (ACET) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.

The average of price targets set by Wall Street analysts indicates a potential upside of 319.6% in Adicet Bio (ACET). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial...

Johnson & Johnson lessened its stake in Adicet Bio, Inc. (NASDAQ:ACET - Free Report) by 93.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 22,779 shares of the company's stock after selling 341,693 shares during the quart...

Adicet Bio (NASDAQ:ACET) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at...

Shares of Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold ra...

Adicet Bio (NASDAQ:ACET) Stock Price Crosses Below 200-Day Moving Average - Time to Sell...